T32-supported Immunology and Rheumatology Postdoctoral Fellows will undertake two years of training in either translational research in clinical immunology or in clinical investigation. Applicants for T32 support will be M.D., Ph.D. or M.D./Ph.D. degree holders. Candidates for postdoctoral fellowships will be reviewed and selected by a Postdoctoral Committee composed of representatives of the two Rheumatology Divisions. The clinical years of postdoctoral fellowship in rheumatology for MDs, not covered by T32 funding will predominantly consist of attendance at outpatient clinics, as well as inpatient consulting. Following clinical training, trainees will select one of two Research Tracks for their T32 training: (i.) The Clinical Immunology Translational Research Track (Track 1);or (ii.) The Clinical Investigation (Track 2). The training in Track 1 will be available for those fellows interested in pursuing translational research in clinical immunology and will be supplemented with required and recommended coursework. A two-year training program in Track 2 can lead to a Master's of Science Degree, administered through the Department of Health Research and Policy. It is our belief that such formal training is important for trainees who pursue a career in clinical research, to provide a foundation in the fundamentals of clinical trial design, bioethics, data analysis, and other important issues in clinical research. For all trainees in both Tracks, attendance will be required at weekly lectures in rheumatic diseases, as well as a series of lectures on Responsible Conduct of Research. Postdoctoral trainees are expected to attend weekly Immunology Grand Rounds, Journal Club meetings, the weekly Immunology Seminar Series, and the Annual T32 and Immunology Retreats during all years of training. This will provide interactions between the rheumatology fellows and the many other immunology fellows and students involved in research endeavors at Stanford. In the T32-supported years, MD postdoctoral fellows will attend clinic one or two half-days per week, as well as regular research meetings determined by their individual preceptors. We will leverage Stanford's rich environment to provide many additional opportunities for trainees interested in immunology, proteomics, genomics, clinical trials, and outcomes.
In order to meet future public health needs of the nation this educational training program provides exceptional research training to M.D., M.D./Ph.D., or Ph.D. trainees in adult and pediatric rheumatology and clinical immunology. It will train the next generation of translational and clinical research investigators to take advantage of new breakthroughs in understanding disease pathophysiology and the resultant potential for innovative therapy in both adult and pediatric rheumatic diseases. The long-term goal is to enable the trainees to become independent investigators and academic physician- scientist leaders of the future.
|Geraldino-Pardilla, Laura; Russo, Cesare; Sokolove, Jeremy et al. (2017) Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. Rheumatology (Oxford) 56:534-540|
|Moskowitz, David M; Zhang, David W; Hu, Bin et al. (2017) Epigenomics of human CD8 T cell differentiation and aging. Sci Immunol 2:|
|Sokolove, Jeremy; Schiff, Michael; Fleischmann, Roy et al. (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 75:709-14|
|Macaubas, Claudia; Wong, Elizabeth; Zhang, Yujuan et al. (2016) Altered signaling in systemic juvenile idiopathic arthritis monocytes. Clin Immunol 163:66-74|
|Yiu, Gloria; Rasmussen, Tue K; Ajami, Bahareh et al. (2016) Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1. Arthritis Rheumatol 68:1233-44|
|Postolova, Anna; Chen, Jennifer K; Chung, Lorinda (2016) Corticosteroids in Myositis and Scleroderma. Rheum Dis Clin North Am 42:103-18, ix|
|Cho, Hyunje Grace; Fiorentino, David; Lewis, Matthew et al. (2016) Identification of Alpha-Adrenergic Agonists as Potential Therapeutic Agents for Dermatomyositis through Drug-Repurposing Using Public Expression Datasets. J Invest Dermatol 136:1517-1520|
|Bernet, Laura L; Lewis, Matthew A; Rieger, Kerri E et al. (2016) Ovoid Palatal Patch in Dermatomyositis: A Novel Finding Associated With Anti-TIF1? (p155) Antibodies. JAMA Dermatol 152:1049-51|
|Corey, Daniel M; Rosental, Benyamin; Kowarsky, Mark et al. (2016) Developmental cell death programs license cytotoxic cells to eliminate histocompatible partners. Proc Natl Acad Sci U S A 113:6520-5|
|Sokolove, Jeremy; Wagner, Catriona A; Lahey, Lauren J et al. (2016) Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: a cross-sectional analysis of US veterans. Rheumatology (Oxford) 55:1969-1977|
Showing the most recent 10 out of 46 publications